Key Events This Week
15 Sep: Stock declines 3.73% amid technical momentum shift
16 Sep: Intraday high reached with 7.32% surge
17 Sep: Mojo Grade upgraded to Buy following strong financials
18 Sep: Continued gains close week at Rs.1,769.40 (+3.83%)

Tatva Chintan Pharma Chem Ltd Upgraded to Buy on Strong Financial and Technical Momentum
2026-09-17 08:34:26Tatva Chintan Pharma Chem Ltd has seen its investment rating upgraded from Hold to Buy, reflecting a marked improvement across technical indicators, financial trends, valuation metrics, and overall quality. This upgrade, effective from 16 September 2026, is underpinned by robust quarterly results, bullish technical signals, and a compelling growth trajectory that outpaces broader market benchmarks.
Read full news article
Tatva Chintan Pharma Chem Ltd Sees Bullish Momentum Shift Amid Technical Upgrades
2026-09-17 08:04:49Tatva Chintan Pharma Chem Ltd, a specialty chemicals company, has witnessed a significant shift in its technical momentum, moving from a mildly bullish stance to a more confident bullish trend. This change is underscored by strong signals from key technical indicators such as MACD, Bollinger Bands, and moving averages, alongside an upgraded MarketsMOJO rating from Hold to Buy, reflecting growing investor optimism.
Read full news article
Tatva Chintan Pharma Chem Ltd Surges 7.32% to Day's High of Rs 1646.5 — Outperforms Sector by 6.42 Percentage Points
2026-09-16 15:31:35The Sensex advanced 0.4% on 16 Jun 2026, yet Tatva Chintan Pharma Chem Ltd outpaced the market with a 7.32% gain, reaching an intraday high of Rs 1646.5. This 6.42 percentage-point outperformance over the Specialty Chemicals sector signals a distinctly stock-specific rally rather than a broad market lift.
Read full news article
Tatva Chintan Pharma Chem Ltd Sees Technical Momentum Shift Amid Mixed Market Signals
2026-09-15 08:04:02Tatva Chintan Pharma Chem Ltd, a small-cap player in the specialty chemicals sector, has experienced a notable shift in its technical momentum, moving from a bullish to a mildly bullish stance. Despite a recent downgrade in its Mojo Grade from Buy to Hold, the stock’s technical indicators present a nuanced picture, reflecting both strength and caution as it navigates volatile market conditions.
Read full news article
Tatva Chintan Pharma Chem Ltd Downgraded to Hold Amid Mixed Technical and Valuation Signals
2026-09-14 08:16:16Tatva Chintan Pharma Chem Ltd, a specialty chemicals company, has seen its investment rating downgraded from Buy to Hold as of 11 September 2026. This adjustment reflects a nuanced assessment across four key parameters: quality, valuation, financial trend, and technicals. While the company continues to demonstrate strong quarterly financial performance and market-beating returns, evolving technical indicators and valuation concerns have tempered the overall outlook.
Read full news article
Tatva Chintan Pharma Chem Ltd is Rated Buy
2026-09-11 10:10:44Tatva Chintan Pharma Chem Ltd is rated 'Buy' by MarketsMOJO, with this rating last updated on 28 July 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 11 September 2026, providing investors with the latest insights into the company’s performance and outlook.
Read full news article
Tatva Chintan Pharma Chem Ltd is Rated Buy
2026-08-31 10:10:39Tatva Chintan Pharma Chem Ltd is rated 'Buy' by MarketsMOJO, with this rating last updated on 28 July 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 31 August 2026, providing investors with the latest insights into the company’s performance and outlook.
Read full news article
Tatva Chintan Pharma Chem Ltd is Rated Buy
2026-08-20 10:10:40Tatva Chintan Pharma Chem Ltd is rated 'Buy' by MarketsMOJO, with this rating last updated on 28 July 2026. However, the analysis and financial metrics discussed below reflect the stock's current position as of 20 August 2026, providing investors with the latest insights into the company’s performance and outlook.
Read full news article





